Myeloma is not a common cancer type, accounting for less than 1% of new cancer cases and 10% of blood and bone marrow cancers. Myeloma develops when plasma cells — infection-fighting blood cells in the immune system — become abnormal and grow and divide uncontrollably to become tumors.
Myeloma is a relatively rare cancer — accounting for around 10% of blood cancer cases. It develops in plasma cells — white blood cells that grow in the bone marrow.
Myeloma is a group of cancers with overlapping features — identifying its different forms is challenging — and since every patient’s disease looks different, getting an accurate diagnosis is essential.
City of Hope’s approach to treating myeloma starts with a coordinated, multidisciplinary care team comprising myeloma specialists, whose main goals are controlling your disease so that you can live longer and maintain an active life.
Getting treated for myeloma at City of Hope means you are steps away from labs where new cancer treatments are being developed every day. That proximity means you benefit from something unique in cancer care — “bench-to-bedside” treatment.
A National Cancer Institute-designated comprehensive cancer center, City of Hope has been named one of America's top cancer hospitals by U.S. News & World Report for over a decade. We are among a dozen national centers that treat myeloma with a multidisciplinary team solely focused on this type of cancer.
The center is among the largest programs of its kind in California, seeing hundreds of new patients per year. It leads the development of a diverse portfolio of over 15 active Phase 1 and 2 clinical trials for all multiple myeloma stages.
It aims to make multiple myeloma and related light-chain amyloidosis manageable and nonlethal through immunotherapy and rational combinatorial therapies.
It aggressively pursues research on improved treatments and collaborates with myeloma and amyloid experts nationally and internationally.
Understanding unique issues for older patients; using computer models to predict the toxicity and tailoring treatments for efficacy and fewer side effects
Outpatient bone marrow transplantation, provided by highly trained, experienced nurses
Genetic testing and drug therapy customized to the molecular profile of specific myeloma types
Survivorship clinics that support and monitor patients throughout the disease
Your care includes regular interaction and input from hematologists, oncologists, radiologists and pathologists, nurses, social workers, and specially trained support staff. This team brings together deep experience and diverse perspectives to arrive at the ideal treatment for you.
Advancements and current innovative treatment approaches have resulted in survival rates at City of Hope that exceed the SEER National median survival for multiple myeloma.
Azra Borogovac, M.D., M.S., is a hematologist at City of Hope Orange County Lennar Foundation Cancer Center. For Dr. Borogovac, the patient is the most important part of the medical team. She sees the opportunity to provide care to people with cancer as a privilege.
Maung Myo Htut, M.D., is determined to find more effective treatments for multiple myeloma, a rare blood cancer that strikes about 30,000 Americans each year. He believes the body's own immune system may hold the key.
Amrita Krishnan, M.D., directs the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope's cancer research hospital, seeking to make gains in one of the most rapidly changing areas in cancer research.
Sarah S. Lee, M.D., is an assistant clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation, who studies precision therapy for plasma cell disorders like multiple myeloma and amyloidosis.
Professor, Division of Health Analytics, Department of Computational and Quantitative Medicine
Duarte - Main Campus
Dr. Wang is a molecular epidemiologist whose multifaceted research spans the evaluation of genes and heritability, the physical and social environment, and their interactions in cancer and cardiovascular disease etiologies, leveraging data from large cohort and international consortia.